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ABSTRACT
Background: The susceptibility to adverse outcome from critical illness (occurrence of sepsis, sep-
tic shock, organ dysfunction/failure, and mortality) varies dramatically due to different degrees of 
inflammatory response. An over expression of tumor necrosis factor alpha (TNF-α) can lead to the 
progression of the inflammatory condition. Objective: We assessed the relationship of the genotype 
distribution of -308G >A TNF-α polymorphism with regard to the development of sepsis, septic 
shock, higher organ dysfunction or mortality in critically ill patients. Methods: Observational, hos-
pital-based cohort study of 520 critically ill Caucasian patients from southern Brazil admitted to the 
general ICU of São Lucas Hospital, Porto Alegre, Brazil. Patients were monitored daily from the ICU 
admission day to hospital discharge or death, measuring SOFA score, sepsis, and septic shock occur-
rences. The -308G >A TNF-α SNP effect was analyzed in the entire patient group, in patients with 
sepsis (349/520), and in those who developed septic shock (248/520). Results: The genotypic and al-
lelic frequencies were -308GG = 0.72; -308GA = 0.27; -308AA = 0.01; -308G = 0.85; -308A = 0.15. No 
associations were found with sepsis, septic shock, organ dysfunction, and/or mortality rates among 
the TNF-α genotypes. Our results reveal that the -308G >A TNF-α SNP alone was not predictive of 
severe outcomes in critically ill patients. Conclusion: The principal novel input of this study was the 
larger sample size in an investigation with -308G > A TNF-α SNP. The presence of -308A allele is not 
associated with sepsis, septic shock, higher organ dysfunction or mortality in critically ill patients.
Keywords: polymorphism, single nucleotide; tumor necrosis factor receptor; associated peptides 
and proteins; critical care.
[Braz J Infect Dis 2011;15(3):231-238]©Elsevier Editora Ltda.
INTRODUCTION
Among ICU patients the rate of adverse out-
comes (occurrence of sepsis, septic shock, or-
gan dysfunction/failure, and mortality) is still 
high and often uncontrolled despite efforts.1 The 
susceptibility to adverse outcomes in critically 
ill patients varies dramatically due to different 
degrees of inflammatory response to infec-
tions. This may be due, at least in part, to in-
dividual genetic variables of patients facing 
critical illness. Exo- or endogenous antigens 
initiates signal transduction cascades inside 
cells leading to the translocation of NF-κB into 
the nucleus where it regulates the expression 
of pro-inflammatory cytokines.2-4 Activated 
macrophages secrete pro-inflammatory cy-
tokines like TNF-α which initiates the cascade 
of immunity response.5 TNF-α is a pleiotropic 
cytokine mainly produced by activated mono-
cytes and macrophages, which plays a key role 
in the inflammatory response.6 Inappropriate 
expression or over expression of TNF-α can 
lead to the progression of inflammatory and 
autoimmune diseases, and its administration 
reproduces essentially all the deleterious ef-
fects of endotoxin and/or microorganisms at-
tack, including hypotension, activation of the 
coagulation cascade, and organ dysfunction.7-9 
The TNF-α gene is located in the major his-
tocompatibility complex (MHC) region, and 
a large number of polymorphisms of its pro-
moter have been described.10-12 A single nu-
cleotide polymorphism (SNP) at nucleotide 
-308 (-308G > A, relative to the transcription 
start site) in the TNF-α gene promoter region 
may be important in determining host TNF-α 
response. The SNP -308G > A has been asso-
ciated with inducible levels of TNF-α in vitro, 
where the change of a guanidine (common 
-308G allele) to an adenosine (rare -308A 
allele) results in differential binding of nuclear 
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factors, leading to six to sevenfold increase in the inducible 
level of TNF-α gene transcription.13,14 Thus, the presence 
of -308A allele could be dangerous to critically ill patients. 
The -308 polymorphism could potentially affect the cell-
type and stimulus speci! c regulation of TNF-α synthesis at 
the transcriptional level. A genetic propensity to produce 
elevated TNF-α levels, due to the presence of the -308A al-
lele, may alter the course of an immune response with subse-
quent increased risk of disease.15 Systemic administration of 
TNF-α produces most of the symptoms and signs of sepsis, 
and although a number of studies have found associations of 
the -308A allele with a predisposition to septic shock and/
or outcome from sepsis, ! ndings have been inconsistent.16-24 
In order to clarify the potential role of the -308G>A SNP 
we tested 520 patients for the presence of -308A allele influ-
encing the outcome of critical illness, leading patients to sep-
sis, septic shock, higher organ dysfunction, and/or mortality. 
MATERIALS AND METHODS
This study was an observational, hospital-based cohort 
study of patients admitted to the medical and surgical In-
tensive Care Unit (ICU) of the Hospital São Lucas (HSL) of 
the Pontifícia Universidade Católica do Rio Grande do Sul 
(PUCRS), Brazil, between January 1st, 2004, and December 
31st, 2006. Patients were not eligible if they were diagnosed 
with HIV-infection, taking immunosuppressive drugs, 
pregnant or lactating, or of non-Caucasian ancestry. The 
study was approved by the Research Ethics Committee of 
the institution (protocols #03-01732, and #05-02357; REC 
Tel.: +55+51 33203345). After informed consent was ob-
tained, a total of 520 critically ill adult patients from south-
ern Brazil (277 males and 243 females) admitted to the ICU 
at HSL-PUCRS were included in this study.
Phenotyping
We monitored the patients daily during their entire ICU and 
post-ICU (hospital) stay, to ascertain sepsis and septic shock 
occurrences until hospital discharge or death. For diagnosis 
of sepsis and septic shock we used the American College of 
Chest Physicians/Society of Critical Care Medicine Consen-
sus Conference Criteria.25 For illness severity evaluation we 
used the Acute Physiology and Chronic Health Evaluation 
II (APACHE-II) score obtained on the ICU admission day.26 
Organ dysfunction/failure was evaluated using the Sequen-
tial Organ Failure Assessment (SOFA) score27 obtained dur-
ing the ! rst seven days following ICU admission and at days 
15 and 29. The patients’ follow-up was extended up to the 
entire hospital stay since the ICU admission to a maximum 
of 242 days. Clinical endpoints of the study were discharge 
from the hospital (survivors) or death (non-survivors). 
Mortality was measured in days until death. For those pa-
tients with multiple ICU admission during the study period, 
only data from the ! rst admission was considered.
Genotyping
Five milliliters of blood were collected in a sterile sys-
tem with EDTA and maintained refrigerated at 4ºC or 
frozen at -20ºC until DNA extraction. Genomic DNA 
was isolated from leucocytes by standard procedures 
and maintained at -20°C.28 For genotyping TNF-α 
-308G > A SNP (rs1800629), DNA samples were amplified 
by polymerase chain reaction (PCR) with forward primer 
TNF-α-F 5-AGG CAA TAG GTT TTG AGG G¬CC AT-3 
and reverse primer TNF-α-R 5-ACA CTC CCC ATC CTC 
CCT GCT-3 (Invitrogen-Life Technologies, São Paulo, SP, 
Brazil) in which the underlined nucleotide represents the 
deliberated primer mismatch designed to introduce an 
artificial NcoI restriction site when the G allele is present 
at position -308. A 116 bp PCR product was obtained 
from a 25 ! L reaction mix containing 10-50 ng DNA, 
1 ! M each primer, 0.4 mM dNTP, 1.5 mM MgCl2 and 1 U 
Taq polymerase in Taq 1 x Buffer (LGC Biotecnologia, 
Cotia, SP, Brazil). The reaction was carried in a PTC-
100 thermocycler (MJ Research, Watertown, MA, USA) 
as follows: 95°C for 2 minutes; 35 cycles of 95°C for 
30 sec, 60°C for 15 sec and 74°C for 15 sec; and 74°C 
for 10 minutes for final extension. The PCR amplified 
product (12 µL) was cleaved in an appropriate buffer with 
10 U of the NcoI (5`-C/CATGG-3`; GibcoBRL®-Life Tech-
nologies™, Rockville, MD, USA) in a total volume of 15 µL 
at 37°C for 16 hours, and digested or undigested samples 
were visualized by electrophoresis in 3% agarose gel with 
GelRed Nucleic Acid Stain (Biotium Inc. Hayward, CA) 
against a 100-bp ladder. A single band at 116 bp identified 
-308AA homozygotes, two bands at 96 and 20 bp identi-
fied -308GG homozygotes, and three bands at 116, 96 and 
20 bp indicated heterozygotes at the -308 TNF-α locus. 
Each patient found to have -308AA or -308GA genotypes 
were subjected to a second, independent PCR restriction 
fragment length-polymorphism analysis in order to con-
firm their genotypes.
In order to con! rm that the 116 bp PCR ampli! ed product 
really represented the target product, we performed a sequence 
analysis in MegaBase 1000 capillary DNA sequencer (Amersh-
am Biosciences UK Ltd, Chalfont St Giles, Bucks, UK), also using 
the designed primers (forward and reverse). The sequence ob-
tained was submitted to a nucleotide-nucleotide BLAST online 
alignment (blast, at http://www.ncbi.nlm.nih.gov/BLAST/) with 
the databases, and we found consensus with the Homo sapiens 
tumor necrosis factor-α gene, promoter region (GenBank acces-
sion X02910). All personnel involved in patient care were blind to 
the selection process and genotyping results. Based on the infor-
mation that -308A allele leads to six to sevenfold increase in the 
TNF-α transcription level13,14 we use dominant model to -308A 
allele to perform our analysis. We believe that the co-dominant 
or recessive models are not applicable in this case since there is a 
quantitative transcriptional effect of one allele.
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Statistical analysis
Statistical calculations were performed using the statistical 
package SPSS 13 (SPSS 13.0 for Windows, Chicago, Illinois, 
USA). Unless otherwise stated, continuous variable results 
are expressed as a mean ± standard deviation (SD), and cat-
egorical variables as frequencies and percents. Means were 
compared using one-way analysis of variance, and non-nor-
mally distributed variables were analyzed as non-parametric 
using Mann–Whitney test. For the categorical data we used 
Pearson chi-square test, also used to test for Hardy-Wein-
berg equilibrium. To evaluate the influence of individual 
genotype on the patient outcome, excluding other risk fac-
tors that could influence the outcome, we used binary lo-
gistic regression analysis, incorporating patients with and 
without -308A allele and two main clinical predictors, age, 
and SOFA-1 score. All reported p-values are two-tailed and 
considered statistically signi! cant when 0.05 or less.
RESULTS
A total of 947 patients were admitted to the ICU during 
the study period, of which 535 were eligible for analysis ac-
cording the inclusion/exclusion criteria (Figure 1). We per-
formed the analysis of susceptibility to sepsis, septic shock, 
and mortality according -308G > A SNP using the domi-
nant model to -308A allele (pooling -308GA and -308AA 
genotypes) and con! rming that other important variables, 
such as gender, age, or diagnosis were otherwise matched 
Figure 1: Flow diagram of ICU patients studied between January 2004 and December 2006.
between the two genotype groups (Table 1). The gen-
eral genotypic and allelic frequencies were -308GG = 0.72 
(374/520); -308GA = 0.27 (141/520); -308AA = 0.01 (5/520); 
-308G = 0.85; -308A = 0.15, which did not differ from the 
values expected by the Hardy-Weinberg model (p = 0.391; 
Pearson Chi-square test). The main medical cause of admis-
sion to ICU was sepsis (35%), followed by respiratory failure 
(24%) and the main surgical cause was abdominal (11%). 
In ICU, 67% (349/520) of patients had severe sepsis, and 
71% of them (248/349) evolved to shock. Fluid samples of 
patients with severe sepsis were positive for Gram-negative 
bacteria only in 26% (91/349), Gram-positive bacteria only 
in 5% (18/349); both Gram-negative and positive bacteria 
in 14% (49/3497); fungi only in 2% (7/349) and fungal and 
bacterial infection in 5% (16/349). In 48% (167/349) no 
pathogens were identi! ed. The anatomical distribution of 
the primary site of infection in septic patients was as fol-
lows: 66% (230/349) pulmonary, 24% (84/349) abdominal, 
3% (10/349) urinary, 1% (4/349) central nervous system, 1% 
(3/349) skin, and 5% (18/349) another site. Age, APACHE-II 
and SOFA scores, and mortality rates are shown in Table 1. 
Patient mortality was positively associated with older age, 
higher APACHE-II and SOFA-1 scores, sepsis and septic 
shock occurrences (all p < 0.01; data not shown).
When we analyzed the -308G > A TNF-α SNP effect in 
the overall group patients, in patients with sepsis, and 
in those with septic shock no significant associations 
were found (Table 2). Nevertheless, interestingly, the ! ve 
ICU admissions
n = 947
ICU Patients
n = 860 (100%)
Ready for analysis
n = 535 (62.2%)
Included in the study
n = 520 (97.2%)
Readmissions
N = 87
Excluded because
With HIV-infection (n = 61)
Pregnant or lactanting (n = 22)
Taking immunosuppressive drugs (n = 103)
Age > 18 years (n = 51)
Without consent: refusal (n = 11); not asked (n = 77)
n = 325 (37.8%)
Excluded because
No genotype
n = 15 (2.8%)
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Table 2. Patients’ clinical data according -308G > A tumor necrosis factor-α single nucleotide polymorphism 
genotype groups
 Total With -308A Without -308A p(X2)
Total of ICU patients 520 (100) 146 (28.1) 374 (71.9) 0.391
 With sepsis 349 (67.1) 104 (71.2) 245 (65.5) 0.272X2
 With septic shock 248 (47.7) 68 (46.6) 180 (48.1) 0.750
 ICU+H mortality 171 (32.9) 49 (33.6) 122 (32.6) 0.837
 ICU mortality 239 (46) 67 (45.9) 172 (46.0) 0.984
Septic patients 349 (67.1) 104 (71.2) 245 (65.5) 0.272X2
 With septic shock 248(71.1) 68 (65.4) 180 (73.5) 0.128
 ICU+H mortality 195 (55.9) 58 (55.8) 137 (55.9) 0.980
 ICU mortality 154 (44.1) 45 (43.3) 109 (44.5) 0.834
Septic shock patients 248 (47.7) 68 (46.6) 180 (48.1) 0.750X2
 ICU+H mortality 158 (63.7) 43 (63.2) 115 (63.9) 0.924
 ICU mortality 132 (53.2) 39 (57.4) 93 (51.7) 0.423
Variables are expressed as number (%). Without -308A, -308GG homozygotes to -308G > A TNF-α SNP; With -308A, -308GA hete-
rozygotes and -308AA homozygotes to -308G > A TNF-α SNP; ICU, Intensive Care Unit; ICU+H, Intensive Care Unit and Hospital; 
Mortality, mortality at ICU and ICU plus post-ICU (hospital), measured by number of days; n, number of patients; HW, Pearson 
Chi-square test for Hardy-Weinberg equilibrium; X2, Pearson Chi-square test. The p-value describes a comparison between pa-
tients with and without the data specified at each line and the presence of the -308A allele.
Table 1. Clinical and demographic data of critically ill patients according to the TNFα -308G > A SNP genotype groups
Variables All patients With -308A Without -308A p*
Frequency† 520 (100) 146 (28.1) 374 (71.9) 0.391HW
Male† 277 (54) 74 (50.7) 203 (54.3) 0.559X2
Medical admission 433 (83.2) 121 (27.9) 312 (72.1) 0.440X2
Surgical admission 87 (16.8) 28 (32.4) 59 (67.4) 0.440X2
Sepsis† 349 (67.1) 104 (71.2) 245 (65.5) 0.272X2
Septic shock† 248 (47.7) 68 (46.6) 180 (48.1) 0.750X2
Age (years)‡ 57 (40-71) 55 (39-71) 57.5 (40-71) 0.860MW
APACH II score§ 19.5 (7.8) 19.6 (7.6) 19.4 (8.3) 0.833ST
SOFA-1 score‡ 6 (4-9) 6 (4-9) 6 (4-9) 0.595MW
SOFA-7 score‡ 5 (3-8) 5 (3-8) 5 (3-8) 0.494MW
SOFA-15 score‡ 5 (3-8) 5 ( -8) 5 (3-8) 0.850MW
SOFA-29 score‡ 4 (3-8) 5 (3-9) 3 (3-7) 0.054MW
ICU mortality† 171 (32.9) 49 (33.6) 122 (32.6) 0.837X2
ICU+H mortality† 239 (46) 67 (45.9) 172 (46.0) 0.984X2
Without -308A: -308GG homozygotes to -308G > A TNF-α SNP; With -308A, -308GA heterozygotes and -308AA homozygotes to 
-308G > A TNF-α SNP; APACHE-II, acute physiology and chronic health evaluation II; SOFA, sequential organ failure assessment; 
ICU, intensive care unit; ICU+H, ICU plus hospital; LOS, length of stay; n, number; SD, standard deviation of the mean;  
IQR, interquartile range; ST, Student’s t-test; MW, Mann-Whitney U-test; X2, Pearson Chi-Square test; HW, Pearson Chi-Square 
test for Hardy-Weinberg equilibrium.
* p-value describes a comparison between with -308A allele and without -308A allele groups
† n (%)
‡ median (IQR) 
§ mean (SD) 
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-308AA patients developed sepsis and septic shock. We 
also investigated if -308G > A TNF-α genotypes could be 
affecting organ dysfunction or failure, measured by SOFA 
scores (days 1 to 7, 15, and 29). Our results show that there 
were no statistical associations among -308G > A TNF-α 
genotype groups and SOFA scores in any patient sets (criti-
cally ill patients, septic or septic shock patients): SOFA me-
dians obtained during ICU stay (measured in days 1 to 7, 
15, and 29; with a total of 2889 data) were similar among 
genotypes (Table 3). Finally, to control for confounding 
variables, we analyzed the SNP impact with the possible 
covariates age and SOFA-1 on the outcome of critical ill-
ness by binary logistic regression model, but none of geno-
type were found to be relevant.
DISCUSSION
In this study patients were recruited from a medical and 
surgical ICU of the Hospital São Lucas. In agreement with 
a recent epidemiological study in a Brazilian hospital in the 
state of Paraná, we found that the main medical cause for 
ICU admission was sepsis (35% against 40% in Kauss et al.29 
recent study), and the mortality rates at ICU plus follow-up 
were 46% in our study compared to 42% in Kauss et al.29
Our study revealed no association between -308G > A 
TNF-α genotypes and adverse outcomes (sepsis, sep-
tic shock, higher organ dysfunction or mortality) from 
critical illness. Our results demonstrated that the -308A 
rare allele frequency was 15%, confirming the trend 
documented in Danish (22%),24 English (20%),23 French 
(18%),17 and Spanish subjects (9%).30 The -308A allele has 
higher level of inducible and constitutional TNF-α,13,14 
but its phenotypical effects in sepsis, septic shock, organ 
dysfunction, and mortality have been contradictory;31 
while it was perceived in some genetic association stud-
ies;16,18 in other it was not present.22-24
Speci! cally, in contrast to our study (n = 520, southern 
Brazilian population), positive associations between -308A 
allele and sepsis, septic shock, higher organ dysfunction, 
and/or mortality were found when Mira et al.17 (n = 89, 
France), Tang et al.18 (n = 112, China), O’Keefe et al.21 
(n = 152, USA), and Watanabe et al.48 (n = 113, Japan) 
studied the -308G > A SNP in their populations. How can 
these differences among studies be explained? Some fac-
tors may contribute to these ! ndings: ! rst, the TNF-α gene 
is in the highly polymorphic 6p21 locus, within the class 
III region for major histocompatibility complex (MHC), 
between lymphotxin α (TNF-b) and lymphotxin b genes.49 
Strong linkage disequilibrium among the alleles creates es-
tablished haplotypes that affect differently TNF-α expres-
sion and activity, and can have diverse effects within each 
studied population. So, the single -308G > A SNP analysis 
can cause conflicting results. Second, the immune response 
involves several molecules (CD14, TLR4, TLR2, MyD88, 
IRAK, NF-kB, and others) codi! ed by other genes that 
can interfere in the inflammatory arena causing mislead-
ing conclusions. Third, the TNF-α gene product can be 
changed at different stages (gene transcription, post-tran-
scription, mRNA stability, cleavage to soluble form, and/
or receptor structure or levels), and it can modify circulat-
ing TNF-α activity during critical illness affecting patient’s 
outcome. Finally, our larger sample size comparing with 
previous studies may have produced the contrasting result, 
although we recognize that Gordon et al.23 suggested that 
Table 3. Sequential organ failure assessment scores according to -308G > A tumor necrosis factor-α single  
nucleotide polymorphism genotype groups
-308G > A TNF-α  n With -308A Without -308A pMW
Critically ill patients 520 146 374 
 SOFA 1-7,15,29 6 (3-8) 6 (3-8) 6 (3-8) 0.932
 SOFA 1-7 6 (3-8) 6 (3-8) 6 (3-8) 0.988
Septic patients 349 104 245 
 SOFA 1-7,15,29 6 (4-9) 7 (4-9) 6 (4-9) 0.924
 SOFA 1-7 7 (4-9) 7 (4-9) 7 (4-9) 0.839
Septic shock patients 248 68 180 
 SOFA 1-7,15,29 7 (5-10) 8 (5-10) 7 (5-10) 0.520
 SOFA 1-7 7 (5-10) 8 (5-10) 7 (5-10) 0.385
Without -308A, -308GG homozygotes to -308G > A TNF-α SNP; With -308A, -308GA heterozygotes and -308AA homozygotes to 
-308G > A TNF-α SNP; n, number of patients; IQR, interquartile range; SOFA, sequential organ failure assessment score obtained 
daily during the first week from the ICU admission (days 1 to 7), and in the days 15 and 29 described as median (IQR); MW, 
Mann-Whitney U-test. The p-value describes a comparison between SOFA scores and the presence of the -308A allele.
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at least 2,000 patients would be necessary to achieve 90% 
power to obtain a p-value of 0.01 in studies involving the 
-308A allele and septic shock.
For negative results, assessment of power to detect 
modest effects is crucial, and along with that, careful as-
sessment of the likelihood of a false-positive ! nding in an 
apparent signi! cant genetic association should also be made. 
So when can we state success in a genetic association study?32 
A meta-analysis suggested that most reported ! ndings of as-
sociation are not correct, and that these false-positives studies 
are probably responsible for the vastness of failures to replica-
tion associations between common variants and complex out-
comes.33 The reasons for this lack of reproducibility have been 
well discussed,34-36 especially between large versus small stud-
ies.35 Our study was designed to achieve the set of guidelines 
proposed by Bogardus et al.37 recently reviewed by Clark and 
Baudouin31 to examine associations among genetic variants 
and risk for and outcome from complex diseases. In addition 
to that, we considered the guidelines stimulate a higher num-
ber of genotype studies by the NCI-NHGRI Working Group 
on Replication in Association Studies.38
We did not measure serum TNF levels to correlate with 
-308G > A alleles because other studies have described this re-
lationship clearly.23,39 Any meaningful interpretation of serum 
TNF levels taken at varying time points after the onset of illness 
and beginning of antibiotics is di! cult.20 Even in the setting of 
acute septic shock, an increased serum TNF is not detectable in 
all patients,40,41 because TNF has a short half-life, and is known 
to be released in pulses,23 so genotype associations that correlate 
with an overall phenotypic response may be more useful than 
correlation with single point cytokine measurements. Even 
that -308G > A SNP seems to have a central role in the TNF-α 
expression, the overall relevance of association studies can be 
widely questioned.42 Considering the main points expressed by 
critical analysis of association studies,43-45 our study has some 
strengths; I) the SNP has biological reasonability, i.e., there is a 
plausible effect of the gene product in infection and sepsis; II) 
we used a quality control system to ensure genotyping accu-
racy (sequencing veri! cation of the DNA ampli! ed fragment, 
black controls, and repetitions) in our lab routine; III) the lab 
technicians were blinded to phenotype and clinical investiga-
tors blinded to genotype; IV) genotype distributions were in 
Hardy-Weinberg equilibrium;45 V) the patients were recruited 
from an unique Caucasian population with similar genetic 
background, mainly of Portuguese ancestry, but descendants 
from Italians, Spanish and Germans have also contributed to 
this gene pool;46,47 VI) we use precise and universal de! nitions 
of sepsis and septic shock, worldwide scores to organ dysfunc-
tion, and days instead of categories to mortality determinations.
We recognize that nor haplotyped-based neither clus-
ter-based TNF gene approach can be a limitation and that 
multiple-marker studies are more precise than the analysis 
of a single target. Further SNP-array investigations in multi-
ple-center should include the TNF SNP alone or in combi-
nation with other functionally relevant mutations. Broader 
advanced studies including additional candidate TNF SNPs 
and genes such as CD14, TLR4 or TLR2 genes could also 
help to re! ne the understanding about sepsis and septic 
shock predisposition. We are presently investigating some 
of these possibilities.
There have been several other -308G > A studies pub-
lished in the critically ill patients with contradictory results. 
Studies involving genetic polymorphisms and clinical con-
ditions in ICU should be explicitly encouraged, but only 
well-powered, and large studies will provide de! nitive an-
swers to this situation. It is important to emphasize that be-
cause sepsis is a dynamic and complex process, it is likely 
that varying and distinct combination of SNPs, as opposed 
to any SNP alone, interface to impact the outcome of criti-
cally ill patients, and we are currently working on that.
CONCLUSION
In conclusion, our results obtained in 520 critically ill pa-
tients from a single ICU center suggest that -308G > A 
TNF-α SNP alone does not play a major role in the outcome 
from the critical illness. The presence of the -308A TNF-α 
allele was not associated to the outcome of sepsis, septic 
shock, higher organ dysfunction or mortality in critically ill 
patients in a population from southern Brazil.
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